| Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study) (NCT07347197) | Heartseed Inc. | 2026-01-01 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease (NCT06774040) | VivaCell Biotechnology España | 2026-01-01 |
| Immunoadsorption in Autoimmune Long COVID (NCT07316127) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2026-01-01 |
| JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer (NCT07336771) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-01-01 |
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma (NCT07480850) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus (NCT07303803) | Shanghai Jiao Tong University School of Medicine | 2026-01-01 |
| Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b (NCT06967987) | Institut Cancerologie de l'Ouest | 2026-01-01 |
| Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab (NCT07276100) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2026-01-01 |
| SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure (NCT07311408) | Jingdong Zhang | 2026-01-01 |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (NCT07575919) | Liping Dou | 2026-01-01 |
| Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY) (NCT06981637) | National Health Research Institutes, Taiwan | 2025-12-31 |
| Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo (NCT07253675) | Shanghai Institute Of Biological Products | 2025-12-31 |
| Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy (NCT07289763) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-12-31 |
| Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study (NCT07203144) | First Affiliated Hospital of Chongqing Medical University | 2025-12-31 |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma (NCT07276386) | H. Lee Moffitt Cancer Center and Research Institute | 2025-12-31 |
| A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients. (NCT07290166) | Fudan University | 2025-12-31 |
| Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention (NCT07318103) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-12-31 |
| TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension (NCT07350070) | Tongji Hospital | 2025-12-31 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment (NCT06501976) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) (NCT05487859) | University of Alabama at Birmingham | 2025-12-31 |
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria (NCT06795373) | Ahuva D Cices | 2025-12-31 |
| A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients (NCT03541486) | Joseph J. Cullen, MD, FACS | 2025-12-31 |
| A Study of B2065 in Patients With Acute Ischemic Stroke (NCT07371624) | Tasly Pharmaceutical Group Co., Ltd | 2025-12-31 |
| Study of ZGGS34 in Participants With Advanced Solid Tumors (NCT07258121) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-12-31 |
| The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients (NCT03301558) | Prim. Priv. Doz. Dr. Daniel Cejka | 2025-12-31 |
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC (NCT07309952) | Yang Hong | 2025-12-31 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing (NCT07141771) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer (NCT07286695) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF) (NCT03180450) | Sclnow Biotechnology Co., Ltd. | 2025-12-31 |
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (NCT07330934) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-12-31 |
| Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer (NCT07401537) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-12-31 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (NCT05275374) | Xynomic Pharmaceuticals, Inc. | 2025-12-31 |
| Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer (NCT07150403) | Federation Francophone de Cancerologie Digestive | 2025-12-31 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (NCT07221357) | Bristol-Myers Squibb | 2025-12-31 |
| Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome (NCT07316595) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2025-12-30 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (NCT07332533) | Shanghai JMT-Bio Inc. | 2025-12-30 |
| Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (NCT07314619) | The First Affiliated Hospital of Zhengzhou University | 2025-12-30 |
| Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction (NCT07132190) | Ayal A. Aizer, MD | 2025-12-30 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors (NCT07272590) | Qilu Pharmaceutical Co., Ltd. | 2025-12-30 |
| A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (NCT07251062) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-12-30 |
| QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer (NCT07283991) | Ruijin Hospital | 2025-12-30 |
| A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors (NCT07321574) | Shanghai AB PharmaTech Ltd. | 2025-12-30 |
| An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA) (NCT07392255) | Complement Therapeutics | 2025-12-30 |
| Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion (NCT07302854) | Xiang Luo | 2025-12-30 |
| Topical Vancomycin for Infection Prophylaxis in TJA (NCT04993027) | Alberta Hip and Knee Clinic | 2025-12-30 |
| Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne (NCT07366229) | Shenzhen People's Hospital | 2025-12-30 |
| Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma (NCT07154082) | Wei Zhang | 2025-12-30 |
| Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation (NCT07318649) | Suzhou Genhouse Bio Co., Ltd. | 2025-12-30 |
| Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) (NCT06405230) | GlaxoSmithKline | 2025-12-30 |
| A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia (NCT07259122) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-30 |
| Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) (NCT07257380) | Shanghai Zhongshan Hospital | 2025-12-30 |
| 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (NCT07310355) | Chengdu StarRay Therapeutics Co., Ltd | 2025-12-30 |
| Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients (NCT07223229) | Elixiron Immunotherapeutics (Hong Kong) Ltd. | 2025-12-30 |
| MA-CRC-II-016 SHR-1811 (NCT07355764) | Peking Union Medical College Hospital | 2025-12-30 |
| Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma (NCT07276698) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2025-12-30 |
| Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease (NCT07629245) | Assistance Publique Hopitaux De Marseille | 2025-12-30 |
| A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (NCT07355010) | Qinglei Gao | 2025-12-30 |
| Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma (NCT07276737) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2025-12-30 |
| IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia (NCT07509086) | The First Hospital of Jilin University | 2025-12-29 |
| A Phase II Study of 9MW3811 in Patients With Pathological Scar (NCT07576608) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-12-29 |
| A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (NCT07277660) | UCB Biopharma SRL | 2025-12-29 |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565) | Incyte Corporation | 2025-12-29 |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH (NCT07335601) | Madrigal Pharmaceuticals, Inc. | 2025-12-29 |
| Tofersen in Non-SOD1 ALS (NCT07294144) | Washington University School of Medicine | 2025-12-29 |
| Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (NCT07480161) | Ankara City Hospital Bilkent | 2025-12-29 |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (NCT07288359) | Novartis Pharmaceuticals | 2025-12-29 |
| A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease (NCT07320456) | Shanghai Municipal Hospital of Traditional Chinese Medicine | 2025-12-29 |
| Saci Nivo Rela for TNBC (NCT06963905) | Yale University | 2025-12-29 |
| A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07225569) | Sanofi | 2025-12-29 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer (NCT07301229) | Shanghai Henlius Biotech | 2025-12-29 |
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) (NCT07109414) | Novita Pharmaceuticals, Inc. | 2025-12-29 |
| A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block (NCT07249827) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2025-12-28 |
| Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular (NCT07352007) | Lei ZHAO | 2025-12-28 |
| Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. (NCT06875791) | Fundacion Clinica Valle del Lili | 2025-12-28 |
| Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (NCT07209332) | Wave Life Sciences USA, Inc. | 2025-12-28 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma (NCT07098364) | Fred Hutchinson Cancer Center | 2025-12-27 |
| Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors (NCT07327411) | Second Affiliated Hospital of Soochow University | 2025-12-27 |
| Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients (NCT07266116) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-12-26 |
| A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure (NCT07265349) | Tasly Pharmaceutical Group Co., Ltd | 2025-12-26 |
| GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma (NCT07138547) | Chinese PLA General Hospital | 2025-12-26 |
| Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients (NCT07043894) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-25 |
| 68Ga-BCMA PET/CT in Multiple Myeloma (NCT07319897) | Peking University First Hospital | 2025-12-25 |
| Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer (NCT07340398) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-12-25 |
| MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma (NCT07359053) | Shanghai 6th People's Hospital | 2025-12-25 |
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT (NCT07327788) | Nanfang Hospital, Southern Medical University | 2025-12-25 |
| Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma (NCT07299149) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-25 |
| Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain (NCT07657390) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-25 |
| A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL (NCT07350850) | Tongji Hospital | 2025-12-25 |
| A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma (NCT07272291) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-25 |
| Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial (NCT06995508) | Roswell Park Cancer Institute | 2025-12-24 |
| β-alanine in the Treatment of Advanced Hepatocellular Carcinoma (NCT07317414) | Peking Union Medical College Hospital | 2025-12-24 |
| Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events (NCT07469098) | Sheba Medical Center | 2025-12-24 |
| ctDNA-guided Treatment Decision-making (NCT07394218) | Fudan University | 2025-12-24 |
| An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania (NCT07288320) | Neurocrine Biosciences | 2025-12-24 |
| Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״ (NCT07390500) | NovaSight | 2025-12-24 |
| The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction (NCT07322432) | VapeAway | 2025-12-24 |
| A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy (NCT07235202) | Shenzhen Majory Biotechnology Co., Ltd. | 2025-12-24 |
| Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer (NCT07371208) | Shanghai Jiao Tong University School of Medicine | 2025-12-24 |
| [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer (NCT07314073) | Asan Medical Center | 2025-12-24 |
| Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (NCT06955169) | RTOG Foundation, Inc. | 2025-12-24 |